Compare STRIDES PHARMA SCIENCE with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs ELDER PHARMA - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE ELDER PHARMA STRIDES PHARMA SCIENCE/
ELDER PHARMA
 
P/E (TTM) x 13.4 -0.2 - View Chart
P/BV x 0.8 0.1 782.3% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 STRIDES PHARMA SCIENCE   ELDER PHARMA
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
ELDER PHARMA
Jun-14
STRIDES PHARMA SCIENCE/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs1,147380 301.8%   
Low Rs642188 341.5%   
Sales per share (Unadj.) Rs317.2491.2 64.6%  
Earnings per share (Unadj.) Rs7.8-3.2 -246.6%  
Cash flow per share (Unadj.) Rs25.114.4 173.9%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs274.3376.5 72.8%  
Shares outstanding (eoy) m89.5020.54 435.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.80.6 487.7%   
Avg P/E ratio x114.0-89.3 -127.7%  
P/CF ratio (eoy) x35.719.7 181.1%  
Price / Book Value ratio x3.30.8 432.4%  
Dividend payout %25.50-   
Avg Mkt Cap Rs m80,0585,833 1,372.4%   
No. of employees `0002.5NA-   
Total wages/salary Rs m4,3412,179 199.2%   
Avg. sales/employee Rs Th11,325.8NM-  
Avg. wages/employee Rs Th1,731.4NM-  
Avg. net profit/employee Rs Th280.1NM-  
INCOME DATA
Net Sales Rs m28,39410,089 281.4%  
Other income Rs m941257 366.6%   
Total revenues Rs m29,33410,346 283.5%   
Gross profit Rs m3,965-792 -500.7%  
Depreciation Rs m1,540361 426.3%   
Interest Rs m1,9622,756 71.2%   
Profit before tax Rs m1,403-3,653 -38.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4363,713 -11.7%   
Tax Rs m97125 77.7%   
Profit after tax Rs m702-65 -1,074.4%  
Gross profit margin %14.0-7.8 -177.9%  
Effective tax rate %6.9-3.4 -202.4%   
Net profit margin %2.5-0.6 -381.8%  
BALANCE SHEET DATA
Current assets Rs m24,8369,240 268.8%   
Current liabilities Rs m18,9939,998 190.0%   
Net working cap to sales %20.6-7.5 -274.0%  
Current ratio x1.30.9 141.5%  
Inventory Days Days7146 153.3%  
Debtors Days Days11360 189.2%  
Net fixed assets Rs m34,28910,124 338.7%   
Share capital Rs m895206 435.1%   
"Free" reserves Rs m23,6515,582 423.7%   
Net worth Rs m24,5467,734 317.4%   
Long term debt Rs m15,5134,889 317.3%   
Total assets Rs m65,43722,882 286.0%  
Interest coverage x1.7-0.3 -527.2%   
Debt to equity ratio x0.60.6 100.0%  
Sales to assets ratio x0.40.4 98.4%   
Return on assets %4.111.8 34.6%  
Return on equity %2.9-0.8 -338.5%  
Return on capital %6.922.3 30.9%  
Exports to sales %03.0 0.0%   
Imports to sales %00.4 0.0%   
Exports (fob) Rs mNA307 0.0%   
Imports (cif) Rs mNA43 0.0%   
Fx inflow Rs m15,697307 5,119.7%   
Fx outflow Rs m735125 586.9%   
Net fx Rs m14,962181 8,252.5%   
CASH FLOW
From Operations Rs m1,87111,754 15.9%  
From Investments Rs m5,826-561 -1,039.4%  
From Financial Activity Rs m-10,157-6,762 150.2%  
Net Cashflow Rs m-2,6154,432 -59.0%  

Share Holding

Indian Promoters % 27.7 39.6 69.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 7.5 504.0%  
FIIs % 8.6 16.8 51.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 36.1 71.7%  
Shareholders   56,241 16,479 341.3%  
Pledged promoter(s) holding % 0.0 77.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   SANOFI INDIA  ABBOTT INDIA  PLETHICO PHARMA  CIPLA  TORRENT PHARMA  

Compare STRIDES PHARMA SCIENCE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

DHFL Saga, Falling Passenger Vehicle Sales, and Top Cues in Focus Today(Pre-Open)

Indian share markets witnessed buying interest on Friday and ended their volatile trading session on a positive note.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of STRIDES PHARMA SCIENCE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES PHARMA SCIENCE. Also includes updates on the valuation of STRIDES PHARMA SCIENCE.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Oct 11, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 8-QTR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS